Gao, Ronglin
Pu, Jincheng
Wang, Yanqing
Wu, Zhenzhen
Liang, Yuanyuan
Song, Jiamin
Pan, Shengnan
Han, Fang
Yang, Lufei
Xu, Xianghuai
Tang, Jianping
Wang, Xuan
Funding for this research was provided by:
National Natural Science Foundation of China (81671598, 81801601)
Natural Science Foundation of Shanghai (20ZR1451400)
Clinical Research Cultivation Project of Tongji Hospital (ITJ(QN)2001)
Science and Technology Commission of Shanghai (20Y11911600)
Shanghai Sailing Program (17YF1417200)
Article History
Received: 14 November 2023
Accepted: 18 November 2023
First Online: 25 November 2023
Declarations
:
: A separate group of investigators is responsible for subject recruitment and ICF. The ICF is detailed in the Additional file InternalRef removed. The outpatient and inpatient patients with active pSS combined with ILD are publicized, and patients who agreed to participate in clinical trials will be included for screening. Before a patient is enrolled in the study, the investigator must give each patient a written informed consent and is obligated to provide a complete and comprehensive briefing to the patient or his/her designated representative about the purpose, procedures, and possible risks of the study. Patients should be made aware of their right to withdraw from the study at any time. It is the investigator's responsibility to obtain ICF before each patient enters the study and to keep it in the study file.
: Not applicable.
: The authors declare no competing interests